Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals, Inc. (AVIR) scores 32 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $0. Quantitative score: 50/100. Qualitative score: 20/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full AVIR analysis on boothcheck